Symmetry Investments LP Invests $551,000 in Humana Inc. (NYSE:HUM)

Symmetry Investments LP acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,171 shares of the insurance provider's stock, valued at approximately $551,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox increased its stake in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. raised its stake in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank purchased a new stake in shares of Humana during the 4th quarter valued at $416,202,000. Pzena Investment Management LLC increased its holdings in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Finally, Boston Partners raised its position in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after buying an additional 893,637 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

HUM stock traded down $3.23 during trading on Monday, hitting $261.18. 351,151 shares of the company's stock traded hands, compared to its average volume of 1,741,739. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The stock has a fifty day moving average price of $266.35 and a two-hundred day moving average price of $270.81. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $31.52 billion, a price-to-earnings ratio of 26.25, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.36%. Humana's payout ratio is 35.58%.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of research reports. StockNews.com raised Humana from a "hold" rating to a "buy" rating in a research report on Monday, April 7th. Mizuho boosted their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Truist Financial raised their target price on shares of Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research note on Friday, April 11th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective on the stock. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.